1/255
Looks like no tags are added yet.
Viruses
Obligate intracelluar microbes
smallest infectious agents known
incapable of growth or replication outside of a living cell
upon entry of virus into a host cell, the cell becomes a “Virus factory” for production of virions
Virsu classifications
Classified as DNA or RNA
Viral genomes are either DNA or RNA (not both)
single strand or double strand DNA or RNA
linear or circular
Viral structure
Genome
Capsid
Envelope
Nucleocapside
Capsomeres
Viral Genome
Inner nucleic acid core
DNA (ss or ds) or RNA
Viral capsid
Structural protein that surrounds and protects the nucleic acid
made of capsomeres
Envelope- virus
found on larger viruses
lipid rich- surrounds virion
Responsible for virus entry into host cell
may contain glycoprotein spikes, hemagglutinin, neuraminidase, and other structures that stabilize viral attachment to host cell
Nucleocapsid
Nucleic acid genome surrounded by a protein coat (capsid_
nucleic acid+ capsid
Capsomeres
repeating structural units of a capsid
capsomeres form capsids and characterisitic virus structure
Step of virus replication
aka infection of host
Attach/ absorption
Get inside host cell/ penetration
Expose nucleic acid/ uncating
makie viral components
assmeble virion
release or integrate
Attach - virus
First step up virus replication
recognition of suitable host cell
specific binding fo virus to host cell
Viral tropism
Viral tropism
certain predalection virus ahs for a cell
ex. hepatitis viruses have a liver tropism
Penetration- virus
Second step of virus replication
mechanism of virus entry into host cell involving
internalization of virus into host cell
fusion of neighboring host cells to form multinucleated cells
Syncytis
multinucleated cells
Expose nucleic acid
Aka uncoating
3rd step of viral replication
removal of outer viral capsid
Make viral component
4th step of viral replication
macromolecular biosynthesis
production of viral nucleic acids, proteins
Assemble the virion
Viral components assemble into virus particle
nucleic acids, proteins, capsids
Viral assembly
fifth step of viral repliation
Release/ integrate- virus
Release from or integrate into host cell
host cells lysis or budding from cytoplasm with minimal damage to host or integrate into the genome
6th step of viral replication
Lysis
release of viral particles from lysed host cells
vegetative virus state
Lysogeny
integration of viral nucleic acid into host genome
provirus state/ prophage
Types of Virus Pathogensis
Acute viral infection
LAtent Viral infection
Chronic viral infection
Acute viral infection
has evident signs and symptoms
Latent viral infection
has no visible signs or symptoms, but virus is present in host cells in lysogenic state
inserted into host genome and is inactive until later manifestation
Chronic viral infection
persistent
low levels detected
degree of signs and symptoms vary
transmission via fecal oral route or sexually
Measles disease prgrasssion
viral entry into host followed by viremia
inoculation of secondary target tissue distant from primary site
tissue tropism
Second viremia may occur in tissue- specific manner
Symptoms appear
disease resolution occurs and prevents continued viral replication specific antibody response, cell mediated immunity
Tissue damage can result by
lysis of virus-infected host cells
immunopathologic mechanisms directed against virus that also injures host cells
oncogenic potential of some viruses: stimulate uncontrolled growth of host cells
Host response to viral infection
innate
production of anti viral proteins
Adaptive
production of antibodies
activation of cell mediated immunity
Production of anti-viral proteins
Interferons
complement cascade activation
damage outermost layer of enveloped viruses
coats receptors of nonenveloped viruses
innate immune response
Interferons
activate natural killer cells
Innate immune resposne
anti viral protein
Production of antibodies- viral
Humoral immunity
IgA- mucosal
IgM- early antibody
IgG- later and continued antibody response: antigen memory
Activation of cell mediated immunity
T- lymphocytes
cytotoxic CD8+, helper cells (CD4+), memory
Methods of viral detection- less common
Use of embryonic eggs
influenza virus is isolated in embryonic eggs
Use of animal inoculation
some coxsackie viruses need mice for isolation
Direct detection of virus- commonly used
immunodiagnostics/ viral serologies
Plaque assays
Molecular methods
PCR, RT- PCR
Immunodiagnositcs/ viral serologies
Paired Sera: Acute, convalescent
direct and indirect immunofluroscent
enzyme immunoassays
EIA or ELISA
Latex agglutination
immunoperozide stain methods
radioimmunoassays
direct detection of virus
Plaque assays
Require cell culture: virus- specific cell lines are needed
living cells are maintained in vitro for virus isolation
direct detection- commonly used
Quantitative Assays
Plaque assays
lytic viruses only
each plaque represents one Plaque forming Unit (PFU)
Plaque assays steps
serial dilution of virion-containing solution
create tissues culture plates
spread diluted virus
overlay with agar- prevents diffusion
count number of plaque
Specimen selection of viral diseases
disease syndrome
symptoms, signs
viral etiologies suspected
Time of the year
ex. winter is flu season
Most viruses enter the host through upper respiratory tract and infect tissues that produce symptoms distant from primary inoculation step
ex. aspetic meningitis caused by an enterovirus may be detected in throat, rectal swab or CSF
Most detected viruses in hospitalized US patients
Herpes, Influenzae, Hepatits, HIV
ID for culture, PCR, assay for antigen detection
Virus prevention
immunization available for some viruses
thorough and regular hand washing
avoid contact with people displaying evident signs and symptoms
Fever, cough, diarrhea, respiratory infections
Virus treatment
vaccinations
antivral agents
immune prophylaxis- passive immunity
Antiviral immunity
Approximately 40 antiviral drugs are liscensed for clinical use against
HIV
herpes
Varicella- zoster
cytomegloirus
hepatitis B and C
respiratory syncytial virus
influenza virus
Immune prophylaxis
admin of exogensouly made antibodues to prevent infection in exposed individuals
passive immunity against virus
ex. admin of antibody rich
Viral Hepatitis
Different viruses grouped together, not because of structural or genetic similarities because they share the same tissue tropism
The liver
Many classifications
major significance
not limited by geographical, social, or socioeconomic groupings
some people have no symtpojms
Earlier hepatitis classifications
infectious- transmitted via the fecal oral route
Serum- transmitted via transfusion of infected blood or blood products
Current classifications of Hepatitis
A
B
C
D
E
all are extremly different
Common symptoms of viral hepatits
Fatigue
headache
anorexia
nausea
vomiting
abdominal pain
right upper quadrant or diffuse
Jaundice- most charactersitic
Dark urine- most characterisitc
disease scenarios are similar because of the tissue tropism
Important to know about viral hepatitis
Potential risks for acquiring each type
risk behaviors of the patients
appropriate diagnostic testing
appropriate preventatives/ therapeutics
Viral Hepatitis Panels
set of blood tests that identify markers of hepatitis infection
Viral Hepatitis panels uses
used to diagnose viral hepatitis
used to monitor disease or vaccination status
Diagnose viral hepatits panel use
blood and blood products- hepatits negative products must be avilable
individuals at risk
healthcare works, IV drug users, dialysis patients
Pregnant women- minimize transmission to newborn
determien hepatitis status
ex seroconversion of a patieint from positive to engative hepatitis results
Diagnose active cases
distinguish type of hepatitis
Monitoring disease or vaccination state- viral hepatitis panel
ensure immunity after vaccination
monitor success of immunoprophylaxis
determine HB status: Seroconversion versus carriers
Heptatitis A
HAV
ssRNA virus
fairly simple
Most cases occur in children under 15
some children are asymptomatic
I month of incubation period
infection is self limiting
associated with low mortality, no persistance, no chronic liver damage
picornaviridae
HAV transmission
fecal oral route in most cases
sexual or household contact with infected person
IV drug use
international travel
poor sanitation, poor personal hygiene
HAV individuals at risk
close contact of infected incividual
gay sex
children in daycare centers
travelers
military in areas where clean water and proper sewage disposal is not available
HAV therapy
none available
HAV prophylaxis
immune globulin as pre exposure preventative for travelers
>80% effective
Vaccination of children over 2 years
vaccines provide long term protection
safe effective vaccines available in USA
HAvrix- GlaxoSmith-Kline
Vaqta
HAV prevention
good sanitary habits, practices
short term protection possible with immune globulin
Indivatory os HAV immunity
Presence of total IgG anti-HAV
absence of IgM anti- HAV
Hep A panel
HAV Ag
serum and stool
HAV IgM AB
Serum
HAV IgG Ab
Serum
Hep B
HBV
dsDNA (partially)
enveloped virus
Primarily a blood borne pathogen, low amioutns can be found in
semen, vaginal fluids, Saliva, other body fluids
Contain HBsAg
Hepadnaviridae family
main routes of infection HBV
Percutaneous
through the skin: needles, bites, acupuncture, tattoos, body piercing
Permucosal
through the mucosa: sexual, perinatal, contact such as toothbrush or razor
HBV viral antigens
protein structures that elicit antibody response
Surface- HBsAg
Core- HBcAg
e antigen: HBeAg
People at risk for HBV
Sexual contact of acute or chronically infected person
IV drug users
people with multiple sex partners or history of STD
Infants born to mothers with HBV
Individuals born to mothers with HBV
individuals with occupational contact with blood
recipients of unscreened blood ro blood derived products
hemodialysis patients- due to poor sterilization
Household contact with infected people
institutionalized populaitions
people born in endemic areas
Acute Serological course of HBV
60-90 day incubation
dependent on viral dors, transmission, host factors
CLinical illness occurs in 30-50% of people
Most HBV infected adults recover within 6 months and develop immunity
Some will progress to chronic infection- mostly children
15-25% of chronic HBV pts die due to chronic liver disease
HBV determinants of immunity
Anti- HBs is the only marker for determining immunity
Suggestive indicators are normal enzyme levels adn HBsAG
HBV prevention
Worldwide screening of blood and blood products
destruction of disposable needles
adequate sterilization of reusable instruments
Effective use of Universal precautions and barrier techniques
HBIG
Hepatitis B vaccination
Anti-HBs testing is recommended for certain individuals
Anti-HBs quantitive determinations
HBIG
Hepatitis B immune Globulin
provides temporary, passive HBV protection
Hep B vaccination
1st vaccing produced from plasma of people chronically infected with HBV
current vaccine is produced by recombinant DNA tech
given as IM doses
initial, 30 days later, 6 months after initial dose
Anti HBs testing s recommended for
health care workers
babies born to HBV infected mothers
sex partners of people with chronic HBV infections
immunocompromised individuals
Anti- HBs quantitiative determinations are recommended to
screen individuals to determine need for initial vaccination
if protective antibody levels ar epresent, no need to vaccinate
Est. anti- HBs level after vaccination
determine whether revaccination is needed
How long has it been since initail screening
Assess recovery from HBV infection
HBV antigen ELISA
Anti-HBsAg on microwell is used to “capture” Ag in patient serum
Patient serum with antigen
ANti-HBsAg with enzyme label attached
performance of enzyme reaction
HBV antigen ELISA Interpration
The higher the enzyme activity, the more hepatitis antibody binds to HBsAg in the patient serum
HBV infection markers
Positive- HBsAg
Resolved: antiHBs, anti- HBc total
HBV vaccination: antiHBs
MArkers are not routinely used for diagnostic purposes
all serum
HBV core window
HBsAg neg
Anti-HBs pos
Anti-HBs neg
POSITIV
Anti HBs positive and anti AHBc positive
person who had hepatatis B and completely resolved infectio n
Anti HBs positive
successfully vaxed against hep B
HBV follow up after testing
HBsAg- persistence leads to chronic HBV infection
Anti- HBs- seroconversion from HBsAg to anti HBs positivity indicated resolution of disease and establishment of immunity
HBV complication
chronic infection leads to
liver damage
cirrhosis
hepatic liver cncer
death
Hep C shape
ssRNA positive strand
<50 nm in diameter
blood born
no known cases through other bodily fluids
HCV disease incidence
not well known because acute infection is usually asymptomatic
non specific symptoms may be present
anorexia, malaise, fatigue, abdominal plain
20-30% have jaundice
Individuals may be HCV positive yet have normal liver enzyme results
Main routes of HCV infection
percutaneous
needles, hemodialysis, transfusion of unscreened blood or products, bites, tattoos, acupuncture, body piercing
Permucosal
sexual, perinatal, contact
HCV
leading cause of liver cancer
leading cause for liver transplantation in the US
most pts have chronic disease
estimated 4 million americans are infected
according to WHO- 4% of the world population is infected
Chronic HCV
60-85% of people with HCB
Flaviviridae
Diagnostic testing of HCV
Detection of antibodies specific for HCV (anti-HCV) and ruling out other viruses
antibodies develop within 12 weeks of exposure in 90% of patients
presence of anti-HCV does not distinguish
Acute, chronic, resolved
supplemental tests exists to confirm anti- HCV results
recombinant immunoblot assay RIBA
Current anti- HCV assays have been effective in USA at reducing number of post transfusion cases
PCR for quantitation of HCV viral load
HCV prophylaxis
No vaccine exisits
no short term protection exisits
no immune globulin
HCV therapy
Interferon with or without ribavirin
combo therapy is recommended
HCV protease inhibitors were approved for medical use in USA in 2013
When used in combo with other antiviral drugs, there are 80-90% cure rates with a 12- week treatment course
these drugs are show promise in treatment of HBV and HIV
HCV prevention
recommended by WHO
screening of blood and blood products
destruction of disposibale needles
universal precautions and barrier techniques
education about risks of using unsterilized material and high risk drug and sexual behaviors
HCV panel
HCV RNA- serum
HCV antibody- Seerum
Acute HCV with recovery panel resuls
Anti- HCV palteau
no HCV RNA
no elevated raised ALT
liver function
ALT
alanine transaminase
liver function test
Hep D
HDV
ssRNA virus
<50 nm in diameter
depends on synthesis of HBsAg
cannot infected on its own
Known as delta hepatitis virus
unassigned family
deltavirus- smallest known to man
At risk for HDV
anyone with or at risk for HBV
IV drug users
hemophiliacs/ hemodialysis patients
people with multiple sexual partners
HDV routes of transmission
Similar to those for HBV
usually parenteral
mucosal contact has been reported
perinatal infection is rare
Incidence/ prevalence HDV
infects 4% of acute HBV cases in US
usually corresponds with prevelance of chronic HBV worldwide
HDV acquired as
coinfection with HBV
superinfection
HDV superinfection
HBV carrier becomes infected with HDV
70-80% of chronic HBV carriers with HDV superinfection develop chronic liver disease with cirrhosis compared to 15-30% with chronic HBV alone
HDV prevention
no vaccine exists
immunization with HBV vaccine prevents coinfection
educated people about reducing risks, changing behaviors
HDV therapy
For chronic HBV- HDV infection- follow HBV therapy
no therapy currently exists for chronic hep d patients
HDV panel
HBsAg- serum
HDV RNA- serum
HDV IgM Ab- serum
HDV total AB- serum
Hep E
ssRNA- postive sense
<50 nm
frequently considered water borne enteric agent
HEV transmission
Enteric- fecal oral
ingestion of contaminated water supplies or food
poor personal hygiene
person to person contact
HEV at risk
residents and travelers to endemic regions